Specific Membrane Antigen News Today

Osaka University is starting a Phase I clinical trial (first in human) for refractory prostate cancer using an astatine-labeled drug ([At-211]PSMA-5). This trial aims to evaluate the safety, pharmacokinetics, and efficacy of the new alpha therapy. Previous trials for thyroid cancer have been successful. The trial addresses the high unmet needs of prostate cancer patients and leverages Japan's ability to manufacture astatine. This innovative therapy promises fewer side effects and no need fo...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

Short-sellers appear to be pouncing on an upcoming scientific presentation.

INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. PNT (the "Company" or "POINT"), a company accelerating the discovery, dev

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. ...

05.09.2022 - Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) - POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, ... Seite 1

18.08.2022 - In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 18, 2022 (GLOBE ... Seite 1

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

The wide-ranging market information of the CAR-T Therapy Treatment Market report will surely grow business and improve return on investment (ROI). This market research report gives CAGR values along with their fluctuations for the specific forecast period. The market report has been prepared by taking into account s...

Telix Pharmaceuticals Limited: Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the Companys PSMA 1 targeted prostate cancer...